Brokerages expect that Natera Inc (NASDAQ:NTRA) will announce $66.51 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Natera’s earnings. The highest sales estimate is $69.35 million and the lowest is $65.10 million. Natera posted sales of $53.80 million in the same quarter last year, which would indicate a positive year over year growth rate of 23.6%. The firm is scheduled to report its next earnings report on Tuesday, March 12th.
According to Zacks, analysts expect that Natera will report full year sales of $258.11 million for the current financial year, with estimates ranging from $255.80 million to $261.79 million. For the next fiscal year, analysts anticipate that the firm will post sales of $314.34 million, with estimates ranging from $293.33 million to $339.87 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Natera.
Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.03). The company had revenue of $65.30 million during the quarter, compared to analysts’ expectations of $66.42 million. Natera had a negative net margin of 58.00% and a negative return on equity of 2,569.52%. The business’s revenue for the quarter was up 16.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.51) earnings per share.
Several brokerages have commented on NTRA. BidaskClub upgraded shares of Natera from a “strong sell” rating to a “sell” rating in a research note on Friday. Zacks Investment Research lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Wednesday, November 14th. Cowen reiterated a “buy” rating and issued a $30.00 price target on shares of Natera in a research note on Friday, November 9th. TheStreet lowered shares of Natera from a “c-” rating to a “d+” rating in a research note on Tuesday, October 9th. Finally, JPMorgan Chase & Co. began coverage on shares of Natera in a research note on Friday, October 5th. They issued a “neutral” rating and a $26.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $28.25.
In other news, COO Steven Leonard Chapman sold 35,000 shares of the firm’s stock in a transaction that occurred on Friday, October 12th. The shares were sold at an average price of $20.66, for a total transaction of $723,100.00. Following the transaction, the chief operating officer now directly owns 24,240 shares in the company, valued at $500,798.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 108,108 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $24.31, for a total transaction of $2,628,105.48. Following the transaction, the chief financial officer now owns 22,000 shares in the company, valued at $534,820. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,014,988 shares of company stock worth $48,674,710. Insiders own 13.18% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Tygh Capital Management Inc. grew its position in Natera by 32.3% in the 2nd quarter. Tygh Capital Management Inc. now owns 300,036 shares of the medical research company’s stock valued at $5,647,000 after buying an additional 73,301 shares during the last quarter. Prescott Group Capital Management L.L.C. purchased a new position in Natera in the 2nd quarter valued at $572,000. Harvard Management Co. Inc. purchased a new position in Natera in the 3rd quarter valued at $15,297,000. EAM Investors LLC purchased a new position in Natera in the 2nd quarter valued at $3,868,000. Finally, Gilder Gagnon Howe & Co. LLC purchased a new position in Natera in the 3rd quarter valued at $1,035,000. Institutional investors and hedge funds own 87.90% of the company’s stock.
Natera stock traded down $0.72 during mid-day trading on Wednesday, hitting $16.97. The company had a trading volume of 458,109 shares, compared to its average volume of 700,611. The firm has a market capitalization of $1.09 billion, a P/E ratio of -7.07 and a beta of 2.03. Natera has a 1 year low of $8.60 and a 1 year high of $29.62. The company has a quick ratio of 2.32, a current ratio of 2.44 and a debt-to-equity ratio of 1.30.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Retained Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.